IsoRay (NYSEAMERICAN:ISR) released its quarterly earnings results on Thursday. The healthcare company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02), Morningstar.com reports. The company had revenue of $1.56 million during the quarter, compared to the consensus estimate of $1.73 million.
IsoRay stock opened at $0.39 on Friday. IsoRay has a twelve month low of $0.36 and a twelve month high of $1.22.
Several research firms have weighed in on ISR. Maxim Group cut shares of IsoRay from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research raised shares of IsoRay from a “sell” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright set a $1.00 price target on shares of IsoRay and gave the company a “hold” rating in a report on Wednesday, September 26th.
TRADEMARK VIOLATION NOTICE: “IsoRay (ISR) Announces Quarterly Earnings Results” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/10/isoray-isr-announces-quarterly-earnings-results.html.
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.